New targeted therapy LNCB74 enters human trials for Hard-to-Treat cancers
NCT ID NCT06774963
First seen Jan 06, 2026 · Last updated May 07, 2026 · Updated 19 times
Summary
This early-phase study tests a new drug called LNCB74 in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. LNCB74 is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find a safe dose and to see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer Institute
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hoag Family Cancer Institute
RECRUITINGNewport Beach, California, 92663, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Inova Schar Cancer Institute
RECRUITINGFalls Church, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Intermountain/LDS Hospital Ph 1 Research Program
RECRUITINGSalt Lake City, Utah, 84143, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Theurer Cancer Ctr at Hackensack Univ. Med Ctr.
NOT_YET_RECRUITINGHackensack, New Jersey, 07601, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NEXT Oncology
COMPLETEDSan Antonio, Texas, 78229, United States
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sidney Kimmel Comprehensive Center at Jefferson
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Elizabeth Healthcare
RECRUITINGEdgewood, Kentucky, 41017, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UPMC
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UT Health San Antonio - MD Anderson Cancer Center
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University, Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63108, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.